Monitoring the Effects of Ligustilide on Mice with Idiopathic Pulmonary Fibrosis and Determining the Underlying Mechanism
Received Date: Nov 01, 2022 / Accepted Date: Nov 28, 2022 / Published Date: Nov 29, 2022
Abstract
Idiopathic pulmonary fibrosis is a chronic interstitial lung condition that currently lacks viable treatment options. One of angelica’s key bioactive ingredients is ligustilide (LIG). The current study’s objectives were to investigate the underlying mechanism and monitor the impact of LIG on mice with advanced pulmonary fibrosis lung fibrosis. After a single BLM instillation of 14 days, the mice received daily LIG treatment for 2 weeks. Then the effect of LIG on lung fibrosis was observed then. The impact of LIG on pulmonary fibrosis was assessed using the pulmonary function test, Hematoxylin-Eosin (H&E) and Masson’s trichrome staining, immunofluorescence, and Western blot. Following in vitro therapy with transforming growth factor 1 (TGF-1), we looked into the underlying mechanism.
Citation: Wang J (2022) Monitoring the Effects of Ligustilide on Mice withIdiopathic Pulmonary Fibrosis and Determining the Underlying Mechanism. WorldJ Pharmacol Toxicol 5: 170. Doi: 10.4172/wjpt.1000170
Copyright: © 2022 Wang J. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Open Access Journals
Article Tools
Article Usage
- Total views: 741
- [From(publication date): 0-2022 - May 20, 2024]
- Breakdown by view type
- HTML page views: 586
- PDF downloads: 155
